Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
Fomina et al., Frontiers in Immunology, doi:10.3389/fimmu.2023.1259725
https://c19early.org/fominarg.html